Estimated glomerular filtration rate slope and kidney outcomes in IgA nephropathy
Nephrology Dialysis Transplantation · 16.04.2026
DOI: 10.1093/ndt/gfag089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 16.04.2026. Verfasst von Takaya Sasaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Internal Medicine, the Jikei University School of Medicine, Tokyo, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background and hypothesis In IgA nephropathy (IgAN), early surrogate markers that reflect disease progression are critical for understanding long-term outcomes. While prior studies have suggested a potential role for estimated glomerular filtration rate (eGFR) slope, its validity as a surrogate endpoint requires further validation. We here investigated the association between longitudinal changes in eGFR and kidney outcomes in a large Japanese IgAN cohort.
Methods
Patients with biopsy-confirmed IgAN enrolled in the Japan IgA Nephropathy Cohort Study were analysed. Individual eGFR slopes were estimated using a linear mixed-effects model. The association between eGFR slope and a composite kidney outcome, defined as a ≥40% decline in eGFR or the initiation of kidney replacement therapy, was assessed using joint modeling of longitudinal and survival data, adjusting for clinical and histopathological covariates, including current eGFR levels.
Results
During a median follow-up of 6 years in 937 patients (mean age 39 years; 51% male), 78 patients (8.3%) reached the composite kidney endpoint. Joint modeling analysis demonstrated that a steeper decline in eGFR slope was significantly associated with a higher risk of adverse kidney outcomes [hazard ratio per 1-SD eGFR slope decrease (i.e. 0.31 mL/min/1.73 m2/year steeper decline), 1.82; P < .001]. The association remained statistically significant in sensitivity analyses restricted to patients who had already received treatment at baseline, although the effect size was modestly attenuated. Similar results were observed in an additional sensitivity analysis restricted to patients with at least five available eGFR measurements.
Conclusion
Using joint modeling, we demonstrated that eGFR slope provides prognostic information beyond current eGFR levels in patients with IgAN. Our findings support the use of eGFR slope as a reliable surrogate endpoint for clinical trials and risk stratification in IgAN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Department of Internal Medicine, the Jikei University School of Medicine, Tokyo, Japan.
- Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
ORCID-Profile: Takaya Sasaki, Nobuo Tsuboi, Masahiro Okabe, Keita Hirano, Yusuke Suzuki
Förderung
- Ministry of Health, Labour and Welfare
- Japan Agency for Medical Research and Development
Zitieren
APA
Sasaki, T., Tsuboi, N., Koike, K., Ueda, H., Okabe, M., Yokote, S., Shimizu, A., Hirano, K., Kawamura, T., Yokoo, T., & Suzuki, Y. (2026). Estimated glomerular filtration rate slope and kidney outcomes in IgA nephropathy. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag089
Vancouver
Sasaki T, Tsuboi N, Koike K, Ueda H, Okabe M, Yokote S, et al. Estimated glomerular filtration rate slope and kidney outcomes in IgA nephropathy. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag089
BibTeX
@article{Sasaki2026,
author = {Sasaki, Takaya and Tsuboi, Nobuo and Koike, Kentaro and Ueda, Hiroyuki and Okabe, Masahiro and Yokote, Shinya and Shimizu, Akihiro and Hirano, Keita and Kawamura, Tetsuya and Yokoo, Takashi and Suzuki, Yusuke},
title = {Estimated glomerular filtration rate slope and kidney outcomes in IgA nephropathy},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag089}
}
EUVIMED